Skip to main content

Table 5 Judgment regarding 1 mg uptitration at Week 4

From: Effects of eszopiclone on safety, subjective measures of efficacy, and quality of life in elderly and nonelderly Japanese patients with chronic insomnia, both with and without comorbid psychiatric disorders: a 24-week, randomized, double-blind study

Dose in First Treatment Period, Subgroup (n)

Improved SL and TST at Week 4, n (%)

Not Eligible, n

Eligiblea, n

Elderly

1 mg, with psychiatric disorders (n = 34)

29 (85.3)

32

2

2 mg, with psychiatric disorders (n = 42)

39 (92.9)

41

1

1 mg, without psychiatric disorders (n = 40)

34 (85.0)

38

2

2 mg, without psychiatric disorders (n = 36)

32 (88.9)

35

1

Total elderly (n = 152)

134 (88.2)

146

6

Nonelderly

2 mg, with psychiatric disorders (n = 41)

36 (87.8)

39

2

3 mg, with psychiatric disorders (n = 35)

28 (80.0)

32

3

2 mg, without psychiatric disorders (n = 41)

31 (75.6)

36

5

3 mg, without psychiatric disorders (n = 38)

33 (86.8)

37

1

Total nonelderly (n = 155)

128 (82.6)

144

11

  1. a Patients in the elderly 2-mg group and the nonelderly 3-mg group for whom dose escalation would be appropriate were given a 1-mg placebo tablet.
  2. SL = sleep latency; TST = total sleep time.
Back to article page